Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 9/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199010 | 1.00 | FURIN (0.54) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL29890932 | 1.00 | FURIN (0.54) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL29199011 | 1.00 | FURIN (0.54) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL21551399 | 0.92 | FURIN (0.59) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL21551397 | 0.92 | FURIN (0.59) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL21551401 | 0.92 | FURIN (0.59) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL26077365 | 0.89 | FURIN (0.60) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL24872438 | 0.87 | FURIN (0.59) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL21551019 | 0.87 | FURIN (0.59) | FURINCHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL21551021 | 0.87 | FURIN (0.59) | FURINCHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | FURIN 1/4885CHRM2 3813/4885CHRM1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.